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A B S T R A C T
Purpose
The landscape of managing potential conflicts of interest (COIs) has evolved substantially across
many disciplines in recent years, but rarely are the issues more intertwined with financial and
ethical implications than in the health care setting. Cancer care is a highly technologic arena, with
numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO)
recognizes the role of a professional organization to facilitate management of these interactions
and the need for periodic review of its COI policy (Policy).
Methods
To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were
performed. The first asked ASCO members to estimate opinions of the Policy as it relates to
presentation of industry-sponsored research. Respondents were classified as consumers or
producers of research material based on demographic responses. A similar survey solicited
opinions of nonphysician stakeholders, including patients with cancer, survivors, family members,
and advocates.
Results
The ASCO survey was responded to by 1,967 members (1% of those solicited); 80% were
producers, and 20% were consumers. Most respondents (93% of producers; 66% of
consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated
COIs for presented research. Members favored increased transparency about relationships
over restrictions on presentations of research. Stakeholders (n  264) indicated that disclosure
was “very important” to “extremely important” and preferred written disclosure (77%) over
other methods.
Conclusion
COI policies are an important and relevant topic among physicians and patient advocates. Methods
to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical
for COI management.
J Clin Oncol 31:1677-1682. © 2013 by American Society of Clinical Oncology
INTRODUCTION
The integrity of the medical profession depends
on the ethical values displayed when physicians
interact with patients, colleagues, and the public.
Physician-industry relationships have long been
part of oncology research and practice. These re-
lationships have recently experienced a surge in
public interest, owing to media and government
inquiries about influences on physicians’ profes-
sional judgment.1,2 Several high-profile investiga-
tions led academic institutions and professional
medical organizations to adopt policies govern-
ing physician-researchers’ relationships with
industry3-5 and set the stage for enactment of the
Physician Payments Sunshine Act,6 which will re-
quire public reporting of industry payments
to physicians.
In the health care setting, a conflict of interest
(COI) is a financial or professional stake that com-
promises a physician’s or researcher’s objective
professional judgment. Financial or professional re-
lationships do not necessarily constitute COIs, but
relationships involving financial reward have the
potential to give rise to COIs in almost any aspect of
patient care and medical research. COIs have the
potential to affect how information is presented
in scientific journals and medical education fo-
rums.7,8 As a result, many medical professional
organizations, including the American Society of
Clinical Oncology (ASCO), have COI policies in
place to address the industry relationships held by
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authors, presenters, and others who control the content of pub-
lished and presented information.9-13 In general, these policies rely
on voluntary self-disclosure of relationships that could be viewed
as COIs.
There is no consensus on how best to define, disclose, and man-
age potential COIs. Policies and regulations have implemented a range
of disclosure requirements, management strategies, and restrictions. A
recent commentary in Chest concluded that self-disclosure alone is
insufficient to manage COIs.14 However, policies of recusal and re-
striction were viewed as difficult to employ fairly, whereas enhanced
third-party awareness and evaluation were viewed as critical for suc-
cess. Ultimately, there remains no set standard among medical asso-
ciations, academic institutions, publishers, or other entities about how
to identify and manage COIs. Leaders at the Institute of Medicine, the
Council of Medical Specialty Societies, and other organizations con-
tinue to revise recommendations.15,16
Given the unique role of professional medical organizations in
identifying and managing potential COIs, particularly in research,
members of the ASCO Leadership Development Program (LDP)17
undertook a project to evaluate the ASCO COI Policy (Policy),9 which
was at that time undergoing a process of revision, scheduled for release
in 2013. Currently, the Policy focuses on the principal investigators of
clinical trials and restricts these individuals from presenting research
at ASCO meetings or publishing in ASCO journals if they receive or
hold: (1) stock or equity in a trial sponsor; (2) royalties or licensing fees
from the product or treatment under investigation; (3) travel or trips
paid by the trial sponsor to attend educational or scientific meetings;
(4) honoraria or gifts from the trial sponsor; (5) research-related
payments substantially exceeding actual research costs; or (6) position
as an officer, board member, or employee of the sponsor.11 Exceptions
are made on a case-by-case basis. Certain restrictions also apply to the
ASCO president, president elect, immediate past president, chief ex-
ecutive officer, and editors-in-chief of Journal of Clinical Oncology
(JCO) and Journal of Oncology Practice and a majority of members of
panels involved in guideline development. The LDP considered
whether the Policy was relevant to the current research environment,
user friendly, and sufficiently rigorous to withstand public scrutiny. A
survey explored ASCO members’ perceptions about the Policy and
management strategies. To assess the perceptions of nonphysician
stakeholders concerning COIs, a second survey was directed to pa-
tients with cancer, survivors, family members, and patient advocates.
The scope of the surveys was limited to examination of the Policy as it




An online survey, using the Zoomerang survey tool (http://www.zoo-
merang.com), was offered to ASCO members in membership categories of
active or active junior. The questions were developed during several face-to-
face meetings and conference calls among the authors, consultation with
survey experts, and test-question piloting with other LDP members. ASCO
board members, committee members, and staff were excluded from the
contact list. The final survey distribution list contained 19,238 contacts.
Members were solicited by e-mail communication, with two reminders.
The survey was available for 3 weeks in December 2010 to January 2011.
Responses were voluntary and anonymous and recorded using a Likert
scale, with optional narrative comments permitted.18 The survey was de-
signed to address three primary goals: (1) assess the degree to which
members were aware of the Policy; (2) determine satisfaction with the
Policy rigor; and (3) establish how members felt COIs were best managed.
Consent for participation in the survey was implied by response and
therefore institutional review board exempted.
On the basis of self-reported activities (publication, presentation, session
chair, and so on), respondents were identified as consumers or producers of
scientific material. Survey respondents were asked to report if, in the last 3
years, they had published an article in a peer-reviewed journal (regardless of
authorship position), submitted an abstract to an oncology meeting, partici-
pated as a discussant for an oncology meeting, or chaired a scientific session.
Individuals who responded yes to any of those criteria were coded as produc-
ers; all other respondents were labeled as consumers. The questions posed to
the two groups were similar in content but were worded differently to address
the respective roles.
Stakeholder Survey
This survey was directed to an ASCO distribution list of 483 individuals.
The survey was conducted online using the Zoomerang survey tool, with
Likert-scaled questions with optional narrative response. Responses were so-
licited by e-mail, and the survey was available for 2 weeks in April 2011.
Recipients were encouraged to forward to the survey to friends, family, and
others. The survey was designed to address three primary goals: (1) to what
extent interaction between physicians and industry is viewed as affecting
physician-patient relationships; (2) the context in which physician-researchers
should disclose their industry relationships; and (3) the manner in which COI
information is best conveyed. The survey included 11 questions based on those
used in the member survey, adapted for a lay audience.
Statistical Analysis
Analysis was performed using OpenEpi software (http://www.openepi-
.com) reporting 2 analysis, using a Fisher’s exact test for P value estimation
and a conditional maximum likelihood estimate odds ratio (OR) and mid-P
exact test for upper and lower 95% CIs.
RESULTS
ASCO Member Survey Results
Demographics. The COI survey was administered to ASCO ac-
tive physician members and was open from December 28, 2010, to
January 21, 2011. There were 1,967 member responses to the survey
(1% of membership). Demographic data from the respondents are
listed in Table 1. The majority of respondents (65%) had been ASCO
members for more than 10 years, whereas 20% were 5- to 10-year
members, and 15% had been members for fewer than 5 years. A vast
majority of respondents (73%) were based in the United States, and
only 11% reported employment by the pharmaceutical industry. Al-
though a small representation, the demographics of survey respon-
dents are representative of the ASCO active and active-junior
membership as a whole. On the basis of voluntary responses to a panel
of questions regarding research activities, 80% of the respondents
described themselves as producers of scientific information or re-
search content. The remaining 20% were classified as consumers of
oncology content.
Familiarity and use of Policy. The majority of respondents (93%
of producers; 66% of consumers) felt they were at least familiar with
the Policy (Fig 1A). However, one third of consumers reported lack of
familiarity with the Policy. Only 24% of producers indicated that they
were “very familiar” with the policy. The accuracy of these self-
assessments was not tested.
Regarding use of the COI information reported by ASCO, a
substantial proportion of both producers and consumers reported
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that they “sometimes,” “rarely,” or “never” evaluated COIs (Fig 1B).
This group represented over 50% of consumers and over 20% of
producers. The difference between the consumers and producers who
responded in this manner was also highly significant (OR, 2.764; 95%
CI, 2.199 to 3.475; P  .001). Thus, although substantial effort is
expended to collect and curate COI data on the part of both the
organization and individuals, roughly half of professionals, and in
particular the consumer group, are relying on information presented,
without routinely scrutinizing this information in the context of
the Policy.
Types and degrees of COIs. To assess whether ASCO members
regarded different types of interaction as giving rise to more or less
significant COIs (Table 2), members were asked to rate the so-
called amount of conflict present in several common physician-
industry interactions. Meals and uncompensated consulting were
not viewed as creating significant COIs, whereas stock ownership
and participation in speakers bureaus were consistently viewed as
creating COIs. These views did not appreciably differ between
consumers and producers.
The monetary value of an interaction was also assessed for rele-
vance in perceptions of COIs. Any level of financial exchange was
reported as problematic by 31% of respondents; 29% reported thresh-
olds from $1,000 to $10,000 as problematic; 23% reported $10,000 to
$50,000 as problematic; and 18% reported that relationships valued at
$50,000 or $100,000 or those with no upper ceiling raised concerns.
Strategies to manage COIs. The surveyed members indicated
that COI management was an important issue to the organization and
warranted significant rigor in its application (Fig 1C). There were
numerical differences in this response between consumers and pro-
ducers, with a larger fraction of consumers (57%) feeling that the
Policy could be strengthened in rigor compared with only 35% of
producers. This difference of opinion was also significant (OR, 0.4075;
95% CI, 0.3248 to 0.5106; P  .001), with more producers feeling that
the Policy was sufficiently rigorous.
ASCO implements its Policy through a range of strategies, in-
cluding restrictions on presentation or publication of clinical trial
data. Table 3 summarizes views on which mechanisms for managing
potential COIs are the most effective. Regardless of position as a
consumer or producer, respondents found strategies involving trans-
parency, public disclosure, peer review, external auditing, and presen-
tation of alternative views as more effective measures for managing
COIs, whereas restriction was considered less effective by nearly half
of respondents.
To address future strategies to effectively report and manage
COIs, respondents were asked to select their choice from a list of
options. A substantial proportion of individuals favored strategies that
would increase visibility or transparency of interactions with pharma-
ceutical or industry vendors, but only a minority favored increasing
restrictions on presentation by members with potential conflicts.
Table 1. Demographic Data From Survey Respondents and Self-Designation








 5 290 15 43 11 247 16
6 to 10 390 20 55 14 335 21
 10 1,287 65 292 75 997 63
US based 1,433 73 368 94 1,067 68
Primary employment
Commercial 209 11 37 9 172 11
Noncommercial 1,758 89 353 91 1,407 89
Abbreviation: ASCO, American Society of Clinical Oncology.
Designated based on self-identification as having published a peer-reviewed
manuscript or oncology meeting abstract or served as discussant or chair at an
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Fig 1. American Society of Clinical Oncology member survey key responses.
Members, categorized as producers or consumers of research data, were asked
to indicate (A) their level of awareness of the existing conflict of interest (COI)
policy, (B) how routinely COI information was reviewed in its currently provided
format, and (C) the level of rigor that should be applied to a COI policy revision,
relative to current standards. (*) P  .001.
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Subgroup analysis. No consistent differences were detected be-
tween the responses in the preplanned membership subsets. These
included United States versus international, industry employed versus
nonindustry, and duration of membership.
Nonphysician Stakeholder Survey Results
Demographics. The survey was administered to a distribution of
nonphysician stakeholders, including patients with cancer, survivors,
family members, and patient advocates whose contact information
was available to ASCO. Recipients were encouraged to forward to the
survey to like individuals or groups. The survey was open for responses
from April 7-28, 2011. There were 264 completed surveys. Nearly half
of respondents were age 40 to 60 years (47%), and slightly fewer were
in the 60- to 80-year age range (41%). A majority of respondents
(76%) were women, and 93% identified themselves as patients with
cancer or survivors or family members of a patient with cancer.
Nonphysician stakeholder viewpoints on physician-researcher and
industry partnerships. When respondents were asked if the type of
physician-industry interaction would affect how they viewed the
relationship, 74% said yes. When asked if the dollar amount in-
volved affected how they viewed the relationship, 58% of respon-
dents said yes. Similar to the ASCO member survey, stakeholder
survey respondents indicated a wide range of monetary thresholds
that gave rise to COIs, with answers spread fairly evenly across the
range from any threshold to more than $1 million. Also, in a close
parallel to the responses of ASCO members, certain categories of
physician-industry relationships, such as consulting for pharma-
ceutical companies, receiving company funding for clinical trials,
or owning company stock, were more widely viewed as creating
COIs than other types of relationships.
Viewpoints on disclosure of relationships. The consensus was that
COI disclosure was “very important” to “extremely important” (Fig
2A) in all contexts, including the following: (1) among physician-
researchers; (2) to patients of a physician-researcher; (3) to possible
clinical trial participants; and (4) between physicians and their pa-
tients, even in the clinical care setting not involving a clinical trial.
Unstructured comments indicated that full disclosure was expected
and could be a contributing factor in decisions regarding therapy.
Stakeholders indicated a wide range of opinions but were universal in
their expectation that disclosures be shared freely among parties. Sev-
eral comments were highly informative of the changing nature of COI
disclosure outside the health care system, with respondents observing
that such information was provided as a matter of course in other
professional settings.
Finally, given the multiple constraints placed on physician-
patient interactions and the priorities to discuss clinical, therapeutic,
prognostic, and psychosocial issues during a time-limited encounter,
stakeholders were asked how COI information could be best conveyed
to patients and caregivers. Respondents favored written disclosure
(77%) over other methods (Fig 2B), closely followed by verbal disclo-
sure (53%).
DISCUSSION
Oncology is one of the most active areas for development of novel thera-
peutics. Oncologists in community practice and academia are frequently
involved in drug-development research, leading to interactions and rela-
tionships with the pharmaceutical industry. Initially adopted in 1994, the
ASCOCOIPolicywasdevelopedtoprovideguidanceforthedisclosureof
relationships and COI management in editorial and peer-review activity.
The Policy has been regularly revised, with updates published in 1996,
2003, and 2006 in JCO and a comprehensive revision expected in early
2013.9-13,19 These versions of the Policy created restrictions on principal
investigators engaging in potential COI relationships but also created
situations in which exceptions were necessary or where subjective inter-
pretation of the COI categories was possible. It is not clear if these policies
led to changes in COI practices, but the Policy has brought issues of COI
disclosure and management to a position as a key issue in oncology and
medical practice.
In the context of the upcoming revision and the evolving societal
concerns, an evaluation of the attitudes, perceptions, and expectations
of physicians and nonphysician stakeholders was needed. Although
COI management is important for all medical professionals, oncology
care is a discipline where clinical practitioners are actively involved in
the development of new therapies and is thus a unique brand of
medicine combining extensive physician-industry relationships and
intense physician-patient relationships. The primary intent of this
evaluation was to determine how the ASCO COI Policy could remain
responsive to the current and evolving needs of ASCO members and
other stakeholders.
This survey was the first to our knowledge seeking to measure
and compare the opinions of physicians, considered from the view-
point of both producers (physicians reporting research findings with
potential COIs) and consumers (physicians interpreting such data) as
well as nonphysician stakeholders (including patients with cancer and
Table 2. Common Physician-to-Industry Interactions Where ASCO Members
Indicated Concerning Level of Conflict
Type of Interaction Respondents (%)
Payment for meals 20
Speakers bureau (slides provided) 72




Abbreviation: ASCO, American Society of Clinical Oncology.
Moderate to substantial conflict.





Public disclosure 81 77
Peer review 86 87
Auditing of content 85 83
Alternative views presented 91 88
Restrictions on presenters 58 54
Abbreviations: ASCO, American Society of Clinical Oncology; COI, conflict of
interest.
Effective to extremely effective.
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family members). There are limitations that must be considered when
evaluating these data. The sample represents only approximately 1%
of the survey target population, and the sample population for both
surveys was limited by the short duration of the survey and the solic-
itation method (ie, e-mail). Therefore, respondents may represent a
subpopulation with heightened interest in this topic or other unmea-
sured motivation for completing the survey. Other sources of poten-
tial biases include lack of a validated study of attitudes toward COIs
and reliance on self-reporting of knowledge of the current Policy as
well as unintentional biases in development of questions and
multiple-choice responses, the order in which the answer choices were
presented, and limitations on the number of choices offered. With a
self-administered survey, we were not able to explore the topic or
evaluate responses in greater depth, as one might with focus groups or
structured interviews. Even with an anonymous survey, perceived
social desirability may guide responses rather than the respondents’
true feelings regarding COIs.
Nevertheless, this represents an important, if not exhaustive,
assessment of the ASCO COI Policy with multiple lessons. The major-
ity of respondents valued comprehensive and rigorous disclosure of
potential COIs in ASCO scientific and educational materials. Atti-
tudes regarding COIs and physician-industry relationships differed
according to the nature of the interaction and the amount of money
involved. ASCO member respondents considered certain relation-
ships as particularly associated with COIs, such as stock ownership
and participation in speakers bureaus. Less concern about COIs was
associated with other relationships, such as payment for meals and
uncompensated consulting. Other activities were regarded as having
moderate COI potential (paid consulting and industry-sponsored
research activity). Although the level of compensation from industry
was considered important by both ASCO members and nonphysician
stakeholders, no consensus was evident regarding thresholds for un-
acceptable COIs. These results indicate that it may be useful to disclose
COIs in a tiered manner related to the type of interaction rather than
the dollar amount.
AstudyfindingthatmayhelpguidefuturechangestoCOIpolicyfor
medical organizations is the strong preference for consistent, transparent
disclosureexpressedbythemajorityofphysicianandstakeholderrespon-
dents in all categories. These sentiments are in contrast to the current
environment where COI disclosure standards vary widely across the pol-
icies of institutions, societies, journals, and government entities. The clear
message calling for reliable and accessible COI reporting was considered
in recent revisions to the ASCO Policy.
Overall, the results of these surveys indicate that COI policy is an
important and relevant topic among physicians, patients, and family
members. While this topic has been the subject of significant media
and government attention, interested parties still remain unaware of
current COI policies and guidelines. Clear and consistent reporting
standards will simplify the disclosure process, improve transparency,
facilitate awareness, and reflect responsiveness to the modern era of
COI management.
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Fig 2. Advocate and stakeholder survey key
responses. Respondents were asked (A)
whether information on physician compensa-
tion should be available to patients (asked for
patients considering clinical trials and for any
patient-physician encounters; data presented
are for any patient-physician encounters) and
(B) how such information would be best dis-
closed to patients (answers chosen from a
series of options).
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